查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
移植骨替代物市場：2023 年至 2028 年預測
市場調查報告書
商品編碼
1410016

移植骨替代物市場：2023 年至 2028 年預測

Bone Graft Substitute Market - Forecasts from 2023 to 2028
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 142 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

移植骨替代物市場預計在預測期內複合年成長率為 6.43%。

移植骨替代物用於預防疾病感染和供體部位併發症並減少手術時間。人口中不斷增加的骨骼疾病和整形外科手術是移植骨替代物市場的主要成長要素。此外，由於植入手術數量的增加，牙科產業的需求不斷增加，預計也將在未來幾年推動移植骨替代物市場。此外，技術進步和政府產品核准導致合成骨移植的可及性提高，預計將進一步推動移植骨替代物市場。

骨骼疾病增加

有多種健康狀況與骨骼密度和礦物質有關，包括骨質疏鬆症、骨質缺乏症、佩吉特氏症、成骨不全症和骨關節炎，這些疾病特別會導致肌肉骨骼問題。此類骨相關疾病病例的不斷增加增加了對移植骨替代物的需求，以改善或取代自體骨移植。據世界衛生組織稱，到 2022 年，全球將有約 1.71 人患有肌肉骨骼問題，成為殘疾的主要原因。此外，肌肉骨骼問題是導致殘疾壽命 (YLD) 的最大因素，佔全球整體殘疾壽命的 17%。如果不及時治療，骨骼疾病可能會導致嚴重的健康問題，影響您的身體、心理和情緒健康。隨著病例的增加，這種負面影響預計將推動移植骨替代物市場的發展。

整形外科手術增加

骨骼疾病和骨質疏鬆症的增加導致整形外科手術的增加，推動了移植骨替代物市場。例如，德國Gelenk Klinik醫院每年收治超過24,000名整形外科患者，其中涉及外科手術的病例超過2,400例。 Business Standard 估計美國每年約進行 200 萬例關節重建。

人工植牙需求增加

由於人工植牙手術數量的增加以及患者對微創手術的偏好，牙科領域對移植骨替代物的需求正在增加。市面上有多種移植骨替代物，包括同種異體移植物、自體移植物、異種移植物、鼻竇增高術和上顎竇提升術。據美國植牙牙科學會稱，每年約有 1500 萬美國人用牙橋或牙冠替換缺失的牙齒。此外，《植牙官方雜誌》報道稱，在近 40% 的植入病例中，沒有足夠的骨質使植入正確整合，需要進行骨移植。

人口老化

在高齡化社會中，骨骼密度趨於下降，這是許多骨骼疾病和手術的原因。全球人口老化的加劇顯示未來幾年對移植骨替代物的需求。例如，根據世界衛生組織估計，60歲及以上人口預計將從2020年的10億增加到2030年的14億，2050年將達到21億人。隨著年齡的成長，我們的骨骼變得越來越脆，更容易骨折，因此骨質疏鬆症患者的數量也在增加。根據骨與關節負擔組織的數據，65 歲以上的人中有近四分之三患有肌肉骨骼疾病，這表明移植骨替代物市場正在不斷成長。

市場機會

整形外科和骨骼疾病數量的不斷增加以及對微創外科手術的需求正在推動移植骨替代物市場的發展，為新進入者提供了巨大的機會。此外，有利的政府法規和對移植骨替代物的核准進一步擴大了擴張機會。 2021年，FDA核准了24種移植骨替代物，包括PMMA骨水泥、生物活性玻璃、硫酸鈣、磷酸鈣水泥和雙相磷酸鈣。此外，改善各種牙科、脊椎和整形外科植入的患者體驗和舒適度的技術進步也有望擴大移植骨替代物的市場規模並帶來更多機會。

預計北美在預測期內將大幅成長

預計在預測期內，北美地區將佔據移植骨替代物市場的重要佔有率。造成這一巨大佔有率的因素包括該地區大量骨質疏鬆患者、政府核准和技術進步。例如，根據骨骼健康和骨質疏鬆症基金會的數據，目前約有 5,400 萬美國人患有骨質疏鬆症。此外，在美國，骨質疏鬆症每年導致約 200 萬例骨折，預計每兩名女性中就有一人會在 50 歲時因骨質疏鬆症而發生骨折。此外，Arthrex、強生公司和史賽克公司等市場領先公司在該地區的存在預計也將透過改善准入和產品進步來推動移植骨替代物市場的發展。

主要進展

2023年5月，Royal Biologics推出Bio-Reign 3D移植骨替代物。分解曲線允許骨形成並隨著骨癒合而變得滲透性。 2022年3月，Molecular Matrix宣布合成移植骨替代物Osteo-P®全面商業化。使用超級交聯碳水化合物聚合物（HCCP）技術修復和再生骨骼。 2020年6月，Bioventus推出了新型帶狀移植骨替代物SIGNAFUSE。骨移植的礦物結構由60%羥磷石灰和40%BETA-磷酸三鈣組成。

公司產品

總部位於美國的 Arthrex 專注於整形外科，幫助外科醫生更好地治療患者。該公司的 OSferion 是一種骨傳導移植骨替代物，由 100% BETA-磷酸三鈣製成。強生公司是一家多專業醫療保健公司，自 20 世紀 40 年代以來一直提供服務。 2023 年 5 月，該公司獲得 FDA 批准，可以在反向肩關節置換術中使用 INHANCE(TM) 肩關節系統。該公司提供使用 BETA-磷酸三鈣的合成 Kronos®移植骨替代物(CMF)，有顆粒和預成型件形式。美敦力公司是一家領先的醫療技術公司，提供先進的外科技術解決方案。公司提供的植骨材料包括Grafton（TM）DBF注射液、Infuse（TM）植骨材料、Manifuse（TM）植骨材料、Master Graft（TM）系列，用於微創手術和開放性手術。你可以

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表

第2章調查方法

  • 調查資料
  • 先決條件

第3章執行摘要

  • 研究亮點

第4章市場動態

  • 市場促進因素
  • 市場抑制因素
  • 波特五力分析
  • 產業價值鏈分析

第5章移植骨替代物市場：依類型

  • 介紹
  • 同種異體移植物
  • 骨移植置換
  • 基於細胞的矩陣

第6章移植骨替代物市場：依應用分類

  • 介紹
  • 脊椎融合手術
  • 創傷
  • 關節重組
  • 牙科骨移植
  • 顱顎顏面

第7章移植骨替代物市場：依最終用戶分類

  • 介紹
  • 醫院
  • 專科診所
  • 其他

第8章移植骨替代物市場：按地區

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 其他
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 伊斯拉爾
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 印尼
    • 泰國
    • 其他

第9章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作

第10章 公司簡介

  • Arthrex, Inc.
  • Johnson & Johnson
  • Medtronic plc
  • Stryker Corporation
  • Baxter International Inc.
  • Xtant Medical Holdings, Inc.
  • Integra LifeSciences
  • NuVasive, Inc.
  • Zimmer Biomet Holdings, Inc.
  • Orthofix Holdings, Inc
簡介目錄
Product Code: KSI061615655

The bone graft substitute market is expected to grow at a CAGR of 6.43% during the forecast period.

Bone graft substitutes are used to prevent disease transmission and donor-site complications and reduce operative time. The rising bone diseases and orthopedic surgeries among the population are major growth factors in the bone graft substitute market. Moreover, the increasing demand from the dental sector due to the rising number of implant procedures is also expected to propel the bone graft substitute market in the coming years. Additionally, the technological advancements leading to enhanced synthetic bone graft accessibility coupled with approval of products by the government are further contemplated to boost the bone graft substitute market.

Growing Prevalence of Bone Diseases

There is various health condition related to bone density and minerals such as osteoporosis, osteopenia, Paget's disease, osteogenesis imperfecta, and osteoarthritis, among others creating a musculoskeletal problem. The growing cases of these bone-related diseases are pushing the demand for bone graft substitutes to improve or replace autogenous bone grafts. According to WHO, around 1.71 people had musculoskeletal problems worldwide in 2022 and it is the leading cause of disability. Moreover, musculoskeletal problems are the biggest contributor to years lived with disability (YLD) accounting for 17% of total YLDs globally. Bone disease causes serious health problems affecting physical, mental, and emotional health if not treated on time. The adverse effect along with the rising cases is anticipated to propel the bone graft substitute market.

Rising Orthopedic Surgeries

The rising number of bone diseases and osteoporosis is leading to more orthopedic surgeries and thereby propelling the bone graft substitute market. For instance, Gelenk Klinik Hospital of Germany treats more than 24,000 orthopaedic patients per year with more than 2400 cases involving surgical procedures. Around 2 million joint replacement surgeries happen in the US every year as per the estimates of Business Standard.

Increasing Demand for Dental Implants

The demand for bone graft substitutes in dentistry is rising owing to the growing number of dental implant procedures and patients' preference for minimally invasive procedures. There are several bone graft substitutes available in the market including allograft, autograft, xenograft, alloplastic, and sinus lift. According to the American Academy for Implant Dentistry, approximately 15 million Americans replace missing teeth with bridges and crowns each year, which increases the need for dental implants thereby propelling the bone graft substitutes market. Moreover, in almost 40% of all implant cases, there is insufficient bone to achieve good implant integration, necessitating the use of bone graft replacements as per the Implant Dentistry Official Journal.

Aging Population

Ageing populations are more prone to low bone density leading to numerous bone diseases and surgery. The growing number of ageing people worldwide indicates the need for bone graft substitutes in the coming years. For instance, the number of people aged 60 or above will increase to 1.4 billion by 2030 from 1 billion in 2020 and it is projected to reach 2.1 billion by 2050 as per the WHO estimates. In old age, bones become brittle and there is a higher chance of breaking leading to more cases of osteoporosis in this age group. According to the Bone and Joint Burden Organization, nearly 3 out of 4 people aged 65 or above suffer from musculoskeletal disease indicating the bone graft substitute market expansion.

Opportunities in the Market

The rising orthopedic and bone diseases coupled with the demand for minimally invasive surgical procedures are propelling the bone graft substitute market thereby providing a phenomenal opportunity for new entrants. Moreover, the favorable government regulations and approvals of bone graft substitutes further extend an expansion opportunity. In 2021, there were 24 types of bone graft substitutes approved by the FDA including PMMA Bone Cement, Bioactive Glass, Calcium Sulfate, Calcium Phosphate Cement, and Biphasic Calcium Phosphate among others. Furthermore, the technological advancements to enhance patient experience and comfort in diversified implantation for dental, spinal, and orthopedic are also expected to boost the bone graft substitute market size leading to increased opportunity.

North America is expected to grow considerably during the forecast period

North American region is expected to hold a significant share of the bone graft substitute market during the forecasted period. Various factors attributed to such a significant share are a huge number of osteoporosis cases, government approvals, and technological advancements in the region. For instance, approximately 54 million Americans have osteoporosis currently as per the Bone Health and Osteoporosis Foundation. Moreover, osteoporosis causes around two million broken bones every year in America and one in two women are expected to have a bone fracture by the age of 50 due to osteoporosis. Further, the presence of some of the market leaders such as Arthrex, Johnson & Johnson, and Stryker Corporation in the region is also expected to boost the bone graft substitute market through increasing accessibility and product advancements.

Key Developments

  • In May 2023, Bio-Reign 3D bone graft substitute was launched by the Royal Biologics which is made with a natural hyper-crosslinked carbohydrate polymer. It enables bone formation with its degradation profile, and it becomes radiopaque as the bone heals.
  • In March 2022, the full commercial launch of the Osteo-P® synthetic bone graft substitute was announced by Molecular Matrix. The hyper-crosslinked carbohydrate polymer (HCCP) technology was used to create it to repair and regenerate bone.
  • In June 2020, a new bone graft substitute SIGNAFUSE was launched by Bioventus in a new strip format. The mineral structure of the bone graft was made with 60% hydroxyapatite and 40% beta-tricalcium phosphate.

Company Products

  • Arthrex, a US-based company focuses on orthopaedics to help surgeons better treat their patients. The company offers OSferion which is an osteoconductive bone graft substitute made from 100% beta-tricalcium phosphate.
  • Johnson & Johnson, it is a multi-specialty healthcare company offering services since the 1940s. In May 2023, the company got clearance from the FDA to use its INHANCE™ shoulder system in reverse shoulder replacement surgeries. The company offers synthetic chronOS® Bone Graft Substitute (CMF) made with beta-tricalcium phosphate and it is available as granules and preformed shapes.
  • Medtronic Plc, they are one of the leading medical technology companies which provide advanced surgical technology solutions. The bone grafting substitute offered by the company is Grafton™ DBF inject, Infuse™ Bone Graft, Magnifuse™ Bone Graft, and Mastergraft™ Family for minimally invasive and open procedures.

Segmentation:

By Type

  • Allografts
  • Bone grafts Substitutes
  • Cell-based Matrices

By Application

  • Spinal Fusion
  • Trauma
  • Joint Reconstruction
  • Dental Bone Grafting
  • Craniomaxillofacial

By End-User

  • Hospitals
  • Specialty Clinics
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. BONE GRAFT SUBSTITUTE MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Allografts
  • 5.3. Bone grafts Substitutes
  • 5.4. Cell-based Matrices

6. BONE GRAFT SUBSTITUTE MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Spinal Fusion
  • 6.3. Trauma
  • 6.4. Joint Reconstruction
  • 6.5. Dental Bone Grafting
  • 6.6. Craniomaxillofacial

7. BONE GRAFT SUBSTITUTE MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Specialty Clinics
  • 7.4. Others

8. BONE GRAFT SUBSTITUTE MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. The Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Isral
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations

10. COMPANY PROFILES

  • 10.1. Arthrex, Inc.
  • 10.2. Johnson & Johnson
  • 10.3. Medtronic plc
  • 10.4. Stryker Corporation
  • 10.5. Baxter International Inc.
  • 10.6. Xtant Medical Holdings, Inc.
  • 10.7. Integra LifeSciences
  • 10.8. NuVasive, Inc.
  • 10.9. Zimmer Biomet Holdings, Inc.
  • 10.10. Orthofix Holdings, Inc